IceCure Medical (ICCM) Scheduled to Post Quarterly Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) will be announcing its earnings results before the market opens on Wednesday, April 3rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $1.19 on Thursday. IceCure Medical has a 1-year low of $0.52 and a 1-year high of $1.57. The firm has a market cap of $54.29 million, a price-to-earnings ratio of -3.22 and a beta of 0.75. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.03 and a quick ratio of 3.41. The firm’s fifty day moving average price is $1.31 and its 200 day moving average price is $1.06.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of IceCure Medical in a research note on Wednesday, March 20th. Alliance Global Partners boosted their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a “buy” rating in a research report on Wednesday, March 20th.

Institutional Investors Weigh In On IceCure Medical

Several institutional investors have recently modified their holdings of ICCM. UBS Group AG grew its stake in IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after acquiring an additional 26,919 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of IceCure Medical by 57.2% during the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after purchasing an additional 20,159 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in shares of IceCure Medical by 100.0% during the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after buying an additional 20,000 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of IceCure Medical in the second quarter valued at approximately $78,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.